FibroGen (FGEN)
(Delayed Data from NSDQ)
$1.04 USD
+0.02 (1.96%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for FibroGen, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 148 | 141 | 235 | 176 | 257 |
Cost Of Goods | 19 | 20 | 13 | 9 | 1 |
Gross Profit | 129 | 120 | 222 | 167 | 255 |
Selling & Adminstrative & Depr. & Amort Expenses | 411 | 421 | 511 | 359 | 345 |
Income After Depreciation & Amortization | -282 | -301 | -289 | -192 | -89 |
Non-Operating Income | 10 | 8 | -1 | 5 | 16 |
Interest Expense | 16 | 1 | 1 | 2 | 3 |
Pretax Income | -287 | -295 | -291 | -189 | -77 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 3 | 2 | 1 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -284 | -294 | -290 | -189 | -77 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -284 | -294 | -290 | -189 | -77 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -277 | -289 | -271 | -170 | -72 |
Depreciation & Amortization (Cash Flow) | 5 | 12 | 17 | 22 | 18 |
Income After Depreciation & Amortization | -282 | -301 | -289 | -192 | -89 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 97.30 | 93.58 | 92.35 | 89.85 | 86.63 |
Diluted EPS Before Non-Recurring Items | -2.54 | -3.14 | -3.14 | -2.11 | -0.89 |
Diluted Net EPS (GAAP) | -2.92 | -3.14 | -3.14 | -2.11 | -0.89 |
Fiscal Year end for FibroGen, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 27.14 | 40.13 | 44.32 | 36.16 |
Cost Of Goods | NA | 5.41 | 4.24 | 5.71 | 3.49 |
Gross Profit | NA | 21.73 | 35.89 | 38.61 | 32.67 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 75.92 | 99.37 | 126.66 | 108.77 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -54.19 | -63.48 | -88.05 | -76.10 |
Non-Operating Income | NA | 2.50 | 4.30 | 2.65 | 1.04 |
Interest Expense | NA | 5.07 | 5.02 | 3.07 | 2.37 |
Pretax Income | NA | -56.77 | -64.21 | -88.47 | -77.43 |
Income Taxes | NA | 0.08 | 0.08 | -0.24 | 0.07 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.62 | 0.68 | 0.55 | 0.80 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -56.23 | -63.62 | -87.68 | -76.71 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -56.23 | -63.62 | -87.68 | -76.71 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 98.50 | 98.25 | 97.73 | 94.69 |
Diluted EPS Before Non-Recurring Items | NA | -0.57 | -0.52 | -0.65 | -0.81 |
Diluted Net EPS (GAAP) | NA | -0.56 | -0.65 | -0.90 | -0.81 |